… Our findings show that empagliflozin reduced the risk of cardiovascular death or
hospitalization for heart failure in patients with heart failure and a preserved ejection fraction. This …

… Among patients receiving recommended therapy for heart failure, those in the empagliflozin
group had a lower risk of cardiovascular death or hospitalization for heart failure than those …

… Twenty patients with type 2 diabetes mellitus and chronic, stable heart failure completed a
randomized, placebo-controlled crossover study of empagliflozin 10 mg daily versus placebo. …

… Empagliflozin reduced the risk of cardiovascular death or heart failure hospitalization,
mainly by reducing heart failure hospitalizations. Empagliflozin reduced the risk of heart failure …

… 2 (SGLT2) inhibitors empagliflozin and dapagliflozin … for heart failure in patients with
chronic heart failure with a reduced left ventricular ejection fraction (LVEF) 9,10 . Empagliflozin …

… The HHF outcome was defined as a heart failure discharge diagnosis in the primary … a
broader definition of HHF, defined as a heart failure discharge diagnosis in any position (HHF-…

… to heart failure outcomes in the overall patient population and in subgroups, including
patients with investigator-reported heart failure at baseline, and the effect of empagliflozin on …

… failure events in patients with heart failure and an ejection fraction >40%. Furthermore, because
patients with heart failure … other than heart failure, we report on the effect of empagliflozin …

… trial, empagliflozin was … empagliflozin data on HF outcomes and discuss potential
mechanisms for its benefits in HF with a focus on the potentially significant impact that empagliflozin …

… In conclusion, in patients with heart failure and a reduced ejection fraction, empagliflozin
reduced the risk of inpatient and outpatient worsening heart failure events, benefits that were …